Enzyvant Therapeutics, Inc.

Sumitomo Pharma Co., Ltd. has decided to cut another 400 employees at its US subsidiary Sumitomo Pharma America, Inc. (SPMA) after already reducing headcount there by 500 in an earlier reorganization

ImmunoGen, Inc. and Protagonist Therapeutics, Inc. accomplished in early April what has become increasingly difficult for public biotechnology companies to do when they accessed significant amounts

Myovant Sciences Ltd. , buoyed by the recent upswing in its share price after achieving various milestones it laid out earlier in the year, has rejected an offer valuing it at $2.4bn from majority sha

Dermavant Sciences Inc. is launching its first commercial drug, which management believes has enormous revenue-generating potential in a large therapeutic category – plaque psoriasis. The US Food and